Page 123 - Read Online

Scirpa et al. Vessel Plus 2022;6:52 https://dx.doi.org/10.20517/2574-1209.2021.74 Page 9 of 11

DECLARATIONS
Authors’ contributions
Wrote the entire manuscript: Scirpa R, Russo D
Essential support:Musumeci B
All authors reviewed the final manuscript.

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2022.

REFERENCES
1. Gertz MA, Benson MD, Dyck PJ, et al. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol
2015;66:2451-66. DOI PubMed
2. Connors LH, Lim A, Prokaeva T, Roskens VA, Costello CE. Tabulation of human transthyretin (TTR) variants, 2003. Amyloid
2003;10:160-84. DOI PubMed
3. Rapezzi C, Lorenzini M, Longhi S, et al. Cardiac amyloidosis: the great pretender. Heart Fail Rev 2015;20:117-24. DOI PubMed
4. Suhr OB, Wixner J, Anan I, et al. Amyloid fibril composition within hereditary Val30Met (p. Val50Met) transthyretin amyloidosis
families. PLoS One 2019;14:e0211983. DOI PubMed PMC
5. Ihse E, Rapezzi C, Merlini G, et al. Amyloid fibrils containing fragmented ATTR may be the standard fibril composition in ATTR
amyloidosis. Amyloid 2013;20:142-50. DOI PubMed
6. Mohammed SF, Mirzoyev SA, Edwards WD, et al. Left ventricular amyloid deposition in patients with heart failure and preserved
ejection fraction. JACC Heart Fail 2014;2:113-22. DOI PubMed PMC
7. Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy Diagnosis of cardiac transthyretin amyloidosis. Circulation 2016;133:2404-12.
DOI PubMed
8. Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC working
group on myocardial and Pericardial diseases. Eur Heart J 2021;42:1554-68. DOI PubMed PMC
9. Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am
Coll Cardiol 2019;73:2872-91. DOI PubMed PMC
10. Rapezzi C, Quarta CC, Obici L, et al. Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with
exclusively cardiac phenotype: an Italian perspective. Eur Heart J 2013;34:520-8. DOI PubMed
11. Conceição I, González-Duarte A, Obici L, et al. “Red-flag” symptom clusters in transthyretin familial amyloid polyneuropathy. J
Peripher Nerv Syst 2016;21:5-9. DOI PubMed PMC
12. Cappelli F, Tini G, Russo D, et al. Arterial thrombo-embolic events in cardiac amyloidosis: a look beyond atrial fibrillation. Amyloid
2021;28:12-8. DOI PubMed
13. Rapezzi C, Quarta CC, Riva L, et al. Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol
2010;7:398-408. DOI PubMed
14. Damy T, Kristen AV, Suhr OB, et al; THAOS Investigators. Transthyretin cardiac amyloidosis in continental western europe: an
insight through the transthyretin amyloidosis outcomes survey (THAOS). Eur Heart J ;2019:391-400. DOI PubMed PMC
15. Coelho T, Maurer MS, Suhr OB. THAOS - The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations
in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin 2013;29:63-76. DOI PubMed